Products for Research Use Only

CDDD11-8

CAT: 0804-HY-162037-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-162037-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
CDDD11-8 is an orally active, potent and selective inhibitor of CDK9 and FLT3-ITD, with Ki values of 8 and 13 nM, respectively. CDDD11-8 reduces the proliferation of leukemia cell lines and was particularly effective against those harboring FLT3-ITD mutation[1][2].
CAS Number
2241659-94-7
UNSPSC
12352005
Target
CDK; FLT3
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/cddd11-8.html
Purity
99.62
Solubility
10 mM in DMSO
Smiles
CC1=CN=C(N[C@@H]2CC[C@@H](N)CC2)N=C1C3=CN=C(C=C4)N3C=C4C5=CC=CC=C5
Molecular Formula
C24H26N6
Molecular Weight
398.50
References & Citations
[1]Anshabo AT, et al. An Orally Bioavailable and Highly Efficacious Inhibitor of CDK9/FLT3 for the Treatment of Acute Myeloid Leukemia. Cancers (Basel) . 2022 Feb 22;14 (5) :1113.|[2]Mustafa EH, et al. Selective inhibition of CDK9 in triple negative breast cancer. Oncogene. 2023 Nov 24.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CDK9